Clinical Trials Browser

Phase 2 × HER2-Negative Breast Cancer × pembrolizumab × Clear all

NCT03989089 2024-12-18

Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

Phase 2 Active not recruiting

HER2-Negative Breast Cancer